Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 201

1.

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.

Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström PO, Wallgren A, Stål O, Carstensen J.

Acta Oncol. 2017 Apr;56(4):614-617. doi: 10.1080/0284186X.2016.1273547. Epub 2017 Jan 12.

PMID:
28080180
2.

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.

Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L.

J Clin Oncol. 2016 Jul 1;34(19):2232-8. doi: 10.1200/JCO.2015.65.6272. Epub 2016 May 9.

PMID:
27161974
3.

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.

Hilborn E, Gacic J, Fornander T, Nordenskjöld B, Stål O, Jansson A.

Br J Cancer. 2016 Feb 2;114(3):248-55. doi: 10.1038/bjc.2015.464. Epub 2016 Jan 7.

4.

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK.

Clin Cancer Res. 2016 Mar 15;22(6):1421-31. doi: 10.1158/1078-0432.CCR-15-0857. Epub 2015 Nov 5.

5.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1. Epub 2015 Jul 23.

6.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Epub 2015 Jul 23. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

7.

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.

Karlsson E, Veenstra C, Emin S, Dutta C, Pérez-Tenorio G, Nordenskjöld B, Fornander T, Stål O.

Breast Cancer Res Treat. 2015 Aug;153(1):31-40. doi: 10.1007/s10549-015-3516-y. Epub 2015 Jul 25.

PMID:
26208487
8.

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.

Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J.

Eur J Cancer. 2015 Aug;51(12):1481-9. doi: 10.1016/j.ejca.2015.03.018. Epub 2015 Jun 11.

PMID:
26074397
9.

S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.

Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzén H, Konstantinell A, Fornander T, Nordenskjöld B, Stål O.

Endocr Relat Cancer. 2015 Jun;22(3):331-43. doi: 10.1530/ERC-14-0513.

10.

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study.

Nordenskjöld AE, Fohlin H, Albertsson P, Arnesson LG, Chamalidou C, Einbeigi Z, Holmberg E, Nordenskjöld B, Karlsson P; Swedish Western and Southeastern Breast Cancer Groups..

Ann Oncol. 2015 Jun;26(6):1149-54. doi: 10.1093/annonc/mdv159. Epub 2015 Apr 3.

PMID:
25839671
11.

Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.

Sjöström M, Hartman L, Grabau D, Fornander T, Malmström P, Nordenskjöld B, Sgroi DC, Skoog L, Stål O, Leeb-Lundberg LM, Fernö M.

Breast Cancer Res Treat. 2014 May;145(1):61-71. doi: 10.1007/s10549-014-2936-4. Epub 2014 Apr 9.

PMID:
24715381
12.

C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients.

Hilborn E, Sivik T, Fornander T, Stål O, Nordenskjöld B, Jansson A.

Breast Cancer Res Treat. 2014 May;145(1):73-82. doi: 10.1007/s10549-014-2933-7. Epub 2014 Apr 9.

13.

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group)., McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S.

Lancet. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: Lancet. 2014 Nov 22;384(9957):1848.

14.
15.

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer.

Weiner M, Skoog L, Fornander T, Nordenskjöld B, Sgroi DC, Stål O.

Ann Oncol. 2013 Aug;24(8):1994-9. doi: 10.1093/annonc/mdt159. Epub 2013 May 12.

16.

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.

Rosell J, Nordenskjöld B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmström PO, Wallgren A, Stål O, Carstensen J.

Breast Cancer Res Treat. 2013 Apr;138(2):467-73. doi: 10.1007/s10549-013-2457-6. Epub 2013 Mar 2.

PMID:
23456195
17.

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients.

Göthlin Eremo A, Wegman P, Stål O, Nordenskjöld B, Fornander T, Wingren S.

Oncol Rep. 2013 Apr;29(4):1467-74. doi: 10.3892/or.2013.2261. Epub 2013 Jan 31.

PMID:
23381945
18.

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.

Fohlin H, Pérez-Tenorio G, Fornander T, Skoog L, Nordenskjöld B, Carstensen J, Stål O.

Eur J Cancer. 2013 Apr;49(6):1196-204. doi: 10.1016/j.ejca.2012.12.006. Epub 2013 Jan 8.

PMID:
23305873
19.

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A.

Ann Oncol. 2013 May;24(5):1203-11. doi: 10.1093/annonc/mds627. Epub 2013 Jan 4.

PMID:
23293111
20.

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.

Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjöld B, Stål O.

Breast Cancer Res Treat. 2013 Jan;137(2):397-406. doi: 10.1007/s10549-012-2376-y. Epub 2012 Dec 15.

Supplemental Content

Loading ...
Support Center